Palatin Technologies, Inc. (PTN): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTN POWR Grades
- Sentiment is the dimension where PTN ranks best; there it ranks ahead of 77.31% of US stocks.
- The strongest trend for PTN is in Sentiment, which has been heading down over the past 35 days.
- PTN's current lowest rank is in the Stability metric (where it is better than 4.33% of US stocks).
PTN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for PTN is 0.02 -- better than merely 7.87% of US stocks.
- PTN's price/sales ratio is 130.83; that's higher than the P/S ratio of 98.01% of US stocks.
- As for revenue growth, note that PTN's revenue has grown -264.75% over the past 12 months; that beats the revenue growth of only 0.19% of US companies in our set.
- Stocks that are quantitatively similar to PTN, based on their financial statements, market capitalization, and price volatility, are SMSI, MRIN, ALLT, THRM, and AWRE.
- PTN's SEC filings can be seen here. And to visit Palatin Technologies Inc's official web site, go to www.palatin.com.
PTN Valuation Summary
- PTN's EV/EBIT ratio is -1.6; this is 105.46% lower than that of the median Healthcare stock.
- Over the past 206 months, PTN's price/earnings ratio has gone up 2.8.
- Over the past 206 months, PTN's price/earnings ratio has gone up 2.8.
Below are key valuation metrics over time for PTN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTN | 2021-08-31 | -303.3 | 1.8 | -4.1 | -1.6 |
| PTN | 2021-08-30 | -303.3 | 1.8 | -4.1 | -1.6 |
| PTN | 2021-08-27 | -297.0 | 1.7 | -4.0 | -1.5 |
| PTN | 2021-08-26 | -301.4 | 1.7 | -4.1 | -1.6 |
| PTN | 2021-08-25 | -302.2 | 1.7 | -4.1 | -1.6 |
| PTN | 2021-08-24 | -297.8 | 1.7 | -4.0 | -1.5 |
PTN Growth Metrics
- Its 3 year net cashflow from operations growth rate is now at 89.93%.
- Its 2 year net income to common stockholders growth rate is now at 41.54%.
- Its 2 year cash and equivalents growth rate is now at 245.61%.
The table below shows PTN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.745556 | -24.75327 | -35.46304 |
| 2021-09-30 | 0.259445 | -32.88457 | -36.76834 |
| 2021-06-30 | -0.188597 | -22.64799 | -33.59649 |
| 2021-03-31 | -0.36379 | -20.18807 | -26.96138 |
| 2020-12-31 | -0.452531 | -19.19571 | -26.614 |
| 2020-09-30 | -0.26795 | -9.697942 | -21.86585 |
PTN Stock Price Chart Interactive Chart >
PTN Price/Volume Stats
| Current price | $0.31 | 52-week high | $0.96 |
| Prev. close | $0.28 | 52-week low | $0.26 |
| Day low | $0.29 | Volume | 291,800 |
| Day high | $0.31 | Avg. volume | 1,036,447 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $0.43 | Market Cap | 71.13M |
Palatin Technologies, Inc. (PTN) Company Bio
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
Latest PTN News From Around the Web
Below are the latest news stories about Palatin Technologies Inc that investors may wish to consider to help them evaluate PTN as an investment opportunity.
Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Palatin Technologies (PTN)Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Palatin Technologies (PTN – Research Report) today and set a price target of $2.00. The company's shares closed last Wednesday at $0.41, close to its 52-week low of $0.33. According to TipRanks.com, Higgins is a 3-star analyst with an average return of 4.4% and a 30.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Armata Pharmaceuticals, and Viridian Therapeutics. Currently, the analyst consensus on Palatin Technologies is a Moderate Buy with an average price target of $3.50, implying a 733.3% upside from current levels. In a report released yesterday, H.C. |
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2022 Results - Earnings Call TranscriptPalatin Technologies, Inc. (PTN) Q2 2022 Earnings Conference Call February 15, 2022 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Stephen Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Higgins - Ladenburg... |
H.C. Wainwright Thinks Palatin Technologies’ Stock is Going to RecoverIn a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Palatin Technologies (PTN – Research Report), with a price target of $5.00. The company's shares closed last Tuesday at $0.40, close to its 52-week low of $0.33. According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -17.4% and a 24.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Palatin Technologies is a Moderate Buy with an average price target of $5.00. |
Earnings Scheduled For February 15, 2022Companies Reporting Before The Bell • FirstService (NASDAQ: FSV ) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. • Fidelity National Info (NYSE: FIS ) is likely to report quarterly earnings at $1.90 per share on revenue of $3.71 billion. • Asbury Automotive Group (NYSE: ABG ) is likely to report quarterly earnings at $6.05 per share on revenue of $2.48 billion. • Euroseas (NASDAQ: ESEA ) is projected to report quarterly earnings at $3.23 per share on revenue of $37.40 million. • LGI Homes (NASDAQ: LGIH ) is estimated to report quarterly earnings at $4.20 per share on revenue of $758.08 million. • TC Energy (NYSE: TRP ) is expected to report quarterly earnings at $0.83 per share on revenue of $2.80 billion. • Palatin Technologies (AMEX: PTN ) is... |
Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate UpdateCRANBURY, N.J., Feb. 15, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced… |
PTN Price Returns
| 1-mo | -14.95% |
| 3-mo | -26.19% |
| 6-mo | -42.02% |
| 1-year | -43.64% |
| 3-year | -72.07% |
| 5-year | -27.91% |
| YTD | -39.41% |
| 2021 | -24.30% |
| 2020 | -13.60% |
| 2019 | 10.17% |
| 2018 | -17.35% |
| 2017 | 68.43% |
Continue Researching PTN
Want to see what other sources are saying about Palatin Technologies Inc's financials and stock price? Try the links below:Palatin Technologies Inc (PTN) Stock Price | Nasdaq
Palatin Technologies Inc (PTN) Stock Quote, History and News - Yahoo Finance
Palatin Technologies Inc (PTN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...